Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics in the areas of osteoporosis and oncology. Radius' lead product, TYMLOSÂŽ (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140 under investigation for potential use in hormone-receptor positive breast cancer. Source
No articles found.
With a focus on the development of small molecule drugs for the treatment of cance...
With a focus on the development of small molecu...
Blueprint Medicines is a precision therapy company striving to improve human healt...
Blueprint Medicines is a precision therapy comp...
Tenax Therapeutics is focused on developing and commercializing pharmaceutical pro...
Tenax Therapeutics is focused on developing and...
Assertio Therapeutics is committed to providing responsible solutions to advance p...
Assertio Therapeutics is committed to providing...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a specialty pharmaceutical company th...
Avadel Pharmaceuticals plc (NASDAQ: AVDL) is a ...
Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on...
Deciphera Pharmaceuticals is a clinical-stage b...
Spectrum Pharmaceuticals is a leading biotechnology company with a focus in Oncolo...
Spectrum Pharmaceuticals is a leading biotechno...
Join the National Investor Network and get the latest information with your interests in mind.